These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9289779)

  • 1. [The mechanism of action of hypolipidemic drugs].
    Scheen AJ
    Rev Med Liege; 1997 Jun; 52(6):445-6. PubMed ID: 9289779
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
    Carmena R
    Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
    Ness GC; Zhao Z; Lopez D
    Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of isoprenoids in vascular smooth muscle: potential benefits of statins unrelated to cholesterol lowering.
    Hughes AD
    J Hum Hypertens; 1996 Jun; 10(6):387-90. PubMed ID: 8872802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of HDL in the prevention of cardiovascular events].
    Paragh G; Harangi M
    Orv Hetil; 2001 Jan; 142(3):121-6. PubMed ID: 11217160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    al Rayyes O; Wallmark A; Florén CH
    Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant].
    Stalenhoef AF; Stehouwer CD
    Ned Tijdschr Geneeskd; 2000 Feb; 144(7):308-10. PubMed ID: 10707739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug of the month. Fluvastatin (Lescol)].
    Scheen AJ
    Rev Med Liege; 1997 Jun; 52(6):442-4. PubMed ID: 9289778
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
    Dansette PM; Jaoen M; Pons C
    Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
    Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
    Charmoillaux M; Goudonnet H; Mercenne F; Mounié J; Truchot RC
    Cell Mol Biol; 1991; 37(8):765-71. PubMed ID: 1807786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients.
    Pazzucconi F; Franceschini G; Gianfranceschi G; Campagnoli G; Sirtori CR
    Pharmacol Res; 1996; 34(3-4):131-3. PubMed ID: 9051704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors.
    Sehayek E; Butbul E; Avner R; Levkovitz H; Eisenberg S
    Eur J Clin Invest; 1994 Mar; 24(3):173-8. PubMed ID: 8033951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A; Rovellini A; Fiorenza AM; Sommariva D
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
    Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia.
    Koter M; Franiak I; Broncel M; Chojnowska-Jezierska J
    Can J Physiol Pharmacol; 2003 May; 81(5):485-92. PubMed ID: 12774855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.